Microbiome and Papillary Thyroid Microcarcinoma
Microbiome and Papillary Thyroid Microcarcinoma
It has been shown that gut microbiome and microbiome metabolism can regulate or control the
 initiation of a cancer process. To the best of the investigators knowledge, no study has
 directly shown the relationship of the thyroid microcarcinoma to the human microbiome. In
 this work, the aim is to detect the microbiome in peripheral blood in a patient with a
 thyroid gland carcinoma, and to correlate it with the disease, compared to the microbiome of
 a group of patients who did not find another thyroid gland carcinoma
Measurements of biological markers and tumor cell motility may be useful in predicting early
 whether a papillary thyroid microcarcinoma (PTMC) will develop to invasive carcinoma.
 Ideally, patients at high risk of progression may undergo immediate surgery instead of active
 surveillance and those with a very low likelihood of tumor progression may be included in an
 active surveillance protocol. Future research should focus on the development of new
 predictive early markers of papillary thyroid carcinoma during patient follow-up. From the
 above, it is clear the need to develop a new marker that raises the suspicion of possible
 thyroid microcarcinoma, if it is not preoperatively detected by the needle biopsy method and
 the patient has the indication for surgery for another benign thyroid disease. To date, there
 are no absolute biological and clinical parameters distinguishing a low risk from a high risk
 PTMC. If the fine needle aspiration shows stage V and VI Bethesda classification, and there
 is a high suspicion of PTMC, then questions such as the extent of the surgery, lobectomy or
 total thyroidectomy are beginning to be raised. The next dilemma is lymphadenectomy. The
 dilemma is greater if there are enlarged cervical lymph nodes (diameter over 1 cm in diameter
 of the small axis) and subsequently micromestases are confirmed. Another entity is when the
 cervical lymph nodes are not pathologically enlarged. This clinical situation is often
 emphasized as 60-80% of PTMC patients have metastases. By correlating a possible difference
 in the microbiome of a participants peripheral blood preoperatively, together with the
 imaging data, there may have been another marker of early PTMC detection and patient
 management planning respectively.
Inclusion Criteria:

 -  Patients who are going to have surgery for some thyroid disease, benign or malignant

 Exclusion Criteria:

 -  Recent, less than 3 months, infection of any system

 -  Receiving antibiotic or antiviral medication in the previous trimester

 -  Patient with chronic virus or bacterial infection

 -  Patient with dermatological disease